These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6978919)

  • 1. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
    Nakamura T
    Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental studies on high-dose methotrexate with citrovorum factor chemotherapy for 89Sr-induced osteosarcoma murine model.
    Tomita K
    Jpn J Antibiot; 1986 May; 39(5):1219-27. PubMed ID: 3489843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
    Samuels LL; Straw JA
    Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose methotrexate with citrovorum factor in osteogenic sarcoma--progress report II.
    Jaffe N; Frei E; Traggis D; Cassady JR; Watts H; Filler RM
    Cancer Treat Rep; 1977 Jul; 61(4):675-9. PubMed ID: 301780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Moderate dose methotrexate with citrovorum factor rescue therapy in the treatment of head and neck cancer].
    Inuyama Y; Hiroto I; Taketa C; Horiuchi M; Mashino S; Fujii M; Matsuura S; Satake B; Takeoda S; Nishijima W; Okuda M; Sakaguchi K; Tanigaito Y; Imakirei M; Konno T; Hirokawa T; Takada K; Ono I; Saitoh H; Takemiya S; Shimada F; Omura K; Miyake H; Fujii K; Kawabe Y; Kondoh T; Komiyama S; Yanagida T; Matsumura Y; Hirano M; Araki S
    Gan To Kagaku Ryoho; 1982 Dec; 9(12):2193-200. PubMed ID: 6764099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of solid tumors using high-dose methotrexate and citrovorum factor].
    Baumgartner G; Heinz R; Karrer K; Pridun N; Lutz D
    Osterr Z Onkol; 1977; 3(5-6):141-8. PubMed ID: 300863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
    Perez C; Wang YM; Sutow WW; Herson J
    Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neo-adjuvant therapy in childhood osteogenic sarcoma: a pilot study of selective postoperative chemotherapy based on response to preoperative high-dose methotrexate].
    Sasaki K; Matsuoka H; Murakami T; Fujimoto T; Takayanagi F; Sawai K; Niwa J; Hara K
    Gan To Kagaku Ryoho; 1986 May; 13(5):1837-45. PubMed ID: 3486634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In vitro cytotoxicity of methotrexate].
    Maehara S
    Nihon Seikeigeka Gakkai Zasshi; 1984 Jul; 58(7):677-84. PubMed ID: 6334123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [H-MTX-CF treatment and osteogenic sarcoma (author's transl)].
    Goto M
    Hokkaido Igaku Zasshi; 1981 Mar; 56(2):235. PubMed ID: 6976923
    [No Abstract]   [Full Text] [Related]  

  • 11. Osteogenic sarcoma: state of the art with high-dose methotrexate treatment.
    Jaffe N
    Clin Orthop Relat Res; 1976 Oct; (120):95-102. PubMed ID: 1086179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
    Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
    Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
    Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tissue concentration of methotrexate in osteosarcoma after high-dose infusion].
    Amino K
    Nihon Seikeigeka Gakkai Zasshi; 1982 Aug; 56(8):765-76. PubMed ID: 6984057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [High dose methotrexate with CF rescue therapy in patients with head and neck cancer].
    Inuyama Y; Taketa C; Hiroto I; Fujii M; Takaoka T; Tanaka J; Matsuura S; Satake B; Takeoda S; Nishijima W
    Gan To Kagaku Ryoho; 1984 Sep; 11(9):1823-31. PubMed ID: 6332576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of methotrexate-citrovorum factor (MTX-CF) rescue therapy in a case of malignant histiocytosis with disseminated intravascular coagulation (author's transl)].
    Fukuhara S; Kim R; Aoki Y; Okada S; Yoneda M; Kita K; Nasu K; Tatsumi E; Shirakawa S; Uchino H
    Rinsho Ketsueki; 1981 Jul; 22(7):1145-51. PubMed ID: 6977047
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
    Kickinger W; Ritschl P; Kotz R
    Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selected applications of methotrexate alone and in combination in osteosarcoma.
    Pratt CB
    Cancer Treat Rep; 1981; 65 Suppl 1():107-11. PubMed ID: 6976828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The influence of liver and renal functions on the changes in serum methotrexate (MTX) level in high-dose MTX therapy].
    Sato T; Nakanishi K; Takahashi M; Sato K; Miura T; Kuzuya T; Mizuno M
    Gan To Kagaku Ryoho; 1990 Dec; 17(12):2375-9. PubMed ID: 2260874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial with high-dose methotrexate therapy and citrovorum factor rescue.
    Isacoff WH; Eilber F; Tabbarah H; Klein P; Dollinger M; Lemkin S; Sheehy P; Cone L; Rosenbloom B; Sieger L; Block JB
    Cancer Treat Rep; 1978 Sep; 62(9):1295-304. PubMed ID: 356984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.